Reference number : 172-2021-2022-Q4-987590, amendment number : 1, agreement type : G, recipient legal name : University of Ottawa, recipient country : CA, recipient province : ON, recipient city : Ottawa|Ottawa, recipient postal code : K1N 6N5, program name english : Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives, program name french : Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D, program purpose english : Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas., program purpose french : Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires., agreement title english : Precision targeted mRNA lipid/lipid-polymer nanoparticles for modulation of the tumor microenvironment (TME), agreement title french : Nanoparticules lipidiques et lipidiques-polymères à ARNm ciblées avec précision pour la modulation du microenvironnement tumoral, agreement number : 987590, agreement value : 200000.0, agreement start date : 2022-02-28, agreement end date : 2025-03-31, description english : The tumor microenvironment (TME) is immunosuppressive and presents many challenges to cancer therapies. Modulating TME to be less immunosuppressive will block tumor immune escape and enhance the effects of cancer immunotherapies such as T-cell therapies. However, TME modulating agents need to be selectively delivered to the tumors to protect them from degradation and inducing unwanted toxicity to healthy organs. This project will develop novel nanoparticle systems containing TME modulating messenger RNA (mRNA) and selectively deliver them to tumors to modulate the TME. The team will assess the therapeutic effects of our mRNA-nanoparticle systems in clinically relevant in vitro and in vivo
models. If successful in modulating the TME to be less immunosuppressive, the proposed technologies will have tremendous potential in the advancement of future CAR-T or other types of cellular immunotherapies for solid tumours., description french : Nanoparticules lipidiques et lipidiques-polymères à ARNm ciblées avec précision pour la modulation du microenvironnement tumoral, expected results english : In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems., expected results french : À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides., additional information english : This agreement has been amended 1 time(s). The end date of this agreement has been modified by 364 days., additional information french : Cet accord a été modifié 1 fois.  La date de fin du présent accord a été changé de 364 jours., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada